AstraZeneca(AZN) - 2025 Q3 - Earnings Call Presentation

9M and Q3 2025 Results Conference call and webcast for investors and analysts 6 November 2025 Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: 9M and Q3 2025 Results Conference call agenda | CEO Opening Remarks | Pascal Soriot Chief Executive Officer | | | --- | --- | --- | | Financial Res ...